Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer
The Oncologist · 04.04.2024 · 29 (4) · 342-349
DOI: 10.1093/oncolo/oyad335 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 11.01.2024. Verfasst von David E Gerber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Mixed response (MR), a scenario featuring discordant tumor changes, has been reported primarily with targeted therapies or immunotherapy. We determined the incidence and prognostic significance of MR in advanced non–small cell lung cancer (NSCLC) treated with cytotoxic chemotherapy. Patients and Methods We analyzed patient-level data from ECOG-ACRIN E5508 (carboplatin-paclitaxel + bevacizumab induction followed by randomization to maintenance therapy regimens). For patients with at least 2 target lesions and available measurements after cycle 2, we characterized response as homogeneous response (HR, similar behavior of all lesions), MR (similar behavior but >30% difference in magnitude of best and least responding lesions), or true mixed response (TMR, best and least responding lesions showing different behavior: ≥10% growth versus ≥10% shrinkage). We compared category characteristics using Mann-Whitney U and Chi-square tests, and overall survival (OS) using log-rank test and Cox models.
Results
Among 965 evaluable patients, HR occurred in 609 patients (63%), MR in 208 (22%), and TMR in 148 (15%). Median OS was 13.6 months for HR, 12.0 months for MR, and 7.6 months for TMR (P < .001). Compared to HR, TMR had inferior OS among stable disease cases (HR 1.62; 95% CI, 1.23-2.12; P < .001) and a trend toward inferior OS among progressive disease cases (HR 1.39; 95% CI, 0.83-2.33; P = .2). In multivariate analysis, TMR was associated with worse OS (HR 1.48; 95% CI, 1.22-1.79; P < .001).
Conclusion
True mixed response occurs in a substantial minority of lung cancer cases treated with chemotherapy and independently confers poor prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
- Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
- Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
- Eastern Cooperative Oncology Group Statistical Center, Boston, MA, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Winship Cancer Institute, Emory University, Atlanta, GA, USA.
ORCID-Profile: David E Gerber
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Gerber, D. E., Wang, Y., Ramalingam, S. S., Bhalla, S., Sun, Z., Borghaei, H., Brahmer, J. R., & Schiller, J. H. (2024). Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer. The Oncologist, 29(4), 342-349. https://doi.org/10.1093/oncolo/oyad335
Vancouver
Gerber DE, Wang Y, Ramalingam SS, Bhalla S, Sun Z, Borghaei H, et al. Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer. The Oncologist. 2024;29(4):342-349. doi:10.1093/oncolo/oyad335
BibTeX
@article{Gerber2024,
author = {Gerber, David E and Wang, Yating and Ramalingam, Suresh S and Bhalla, Sheena and Sun, Zhuoxin and Borghaei, Hossein and Brahmer, Julie R and Schiller, Joan H},
title = {Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {4},
pages = {342--349},
doi = {10.1093/oncolo/oyad335}
}
EUVIMED